Looking good ahead now a few highlights20 Nov 2023 07:53
Operational Highlights
• Contracts signed with a top five pharmaceutical company to develop multiple Optimer®
binders as immunohistochemistry (IHC) reagents to support pipeline development and early
discovery targets (Jul 2022)
• Partnership to develop Optimer® therapeutics to block the activity of naturally occurring
antibodies within the body for use as a potential therapy to prevent transplant rejection. (Nov
2022)
• Multiple deals signed with Novavax, a vaccine developer for respiratory diseases, who require
Optimer® binders to improve the selectivity of their Quality Control (QC) assays (Nov 2022)
• Multiple deals signed (and expanded) with a multinational consumer goods company for
Optimer® binders supporting the development of novel direct-to-consumer personal care
products (Jan 2023)
• Partnership with a developer of custom enzymes based in Asia for Optimer® binders to
incorporate into a biosensor for convenient monitoring of the company's manufacturing
processes (Jan 2023)
• Deal signed with Basecure Therapeutics to identify cell-targeting Optimer® binders for potential
as targeted delivery vehicles for siRNA (Jan 2023)
• Optimer®-Fc tools launched to enable immunohistochemistry research and diagnostic
workflows (Mar 2023)
• Patent filed in a collaborative project with NeuroBio to support early diagnostics for Alzheimer’s
disease (Jun 2023)
Post-period end
• A follow-on deal with a US-based vaccine development company to develop Optimer® binders
as QC reagents (Jul 2023)
• Refreshed Board with pre-IPO Chairman and co-founder returning to support and direct the
team to revenue generation & technical delivery (Aug 2023)
• Net of costs, £3.5 million raised to support the Company target to reach an EBITDA and cash
breakeven position within two years (Aug/Sept 2023)
Signed two deals with a top five pharma partner, valued at up to £0.2 million for the
development of tools for use in immunoassays and IHC in detecting neuronal targets (Aug
2023)
• Completed the reset of the fixed cost base to £3.5m per annum, whilst maintaining the ability
to win sales and deliver projects (Sept 2023)
• Process improvements have been successfully trialled and implemented across the platform to
support lower sample requirements, increase capacity and improve project margins (Oct 2023)
• Development of exemplification data, demonstrating Optimer® binders as IHC reagents for
research and diagnostics is underway with promising early results (Oct 2023)
Commenting on the results, Steve Hull, Executive Chairman of Aptamer Group, said: “I am
pleased to return as the Executive Chairman of Aptamer Group. The Company has a leading technology
platform that is in high demand across the life sciences industry, in supporting researchers and
developers overcome many of the limitations of antibodies and allow them to advance novel technology
solutions to drive healthcare forward.